Found 162 articles for: "infliximab"
Effectiveness of Systemic Treatment Agents on Psoriatic Nails: A Comparative Study
September 2013 | Volume 12 | Issue 9 | Original Article | 1039 | Copyright © September 2013
BACKGROUND: Nails, one of the most visible sites of body, are frequently involved in psoriasis and accepted as the most difficult site for topical treatment because of their anatomical structure. Heal...
Read MoreInfliximab-Induced Psoriasis in Treatment of Crohn's Disease-Associated Ankylosing Spondylitis: Case Report and Review of 142 Cases
August 2013 | Volume 12 | Issue 8 | Original Article | 939 | Copyright © August 2013
TNF-alpha inhibitors are used to treat numerous inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease. Recent reports have illustrated the paradoxical development of ps...
Read MoreAssociation Between the Type and Length of Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis
August 2013 | Volume 12 | Issue 8 | Original Article | 899 | Copyright © August 2013
OBJECTIVE: We sought to assess whether the type of TNF inhibitor therapy (soluble receptor versus monoclonal antibody) has an effect on MI risk; and determine whether length of TNF inhibitor therapy h...
Read MoreEfficacy, Tolerability, and Pharmacodynamics of Apremilast in Recalcitrant Plaque Psoriasis: A Phase II Open-Label Study
August 2013 | Volume 12 | Issue 8 | Original Article | 888 | Copyright © August 2013
BACKGROUND: Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II, multicenter, open...
Read MoreEffect of Infliximab on Health-Related Quality of Life and Disease Activity by Body Region in Patients With Moderate-to-Severe Psoriasis and Inadequate Response to Etanercept: Results from the PSUNRISE Trial
August 2013 | Volume 12 | Issue 8 | Original Article | 874 | Copyright © August 2013
BACKGROUND: Treatment with tumor necrosis factor (TNF)-α antagonists is effective in patients with moderate-to-severe plaque psoriasis, including those with impaired health-related quality of life (...
Read MoreComparison of the Efficacy of Biologics Versus Conventional Systemic Therapies in the Treatment of Psoriasis at a Comprehensive Psoriasis Care Center
August 2013 | Volume 12 | Issue 8 | Original Article | 861 | Copyright © August 2013
BACKGROUND: The efficacy of biologic treatment for psoriasis has not been compared to that of conventional systemic therapies and phototherapy outside of clinical trial settings.
DESIGN: Retros...
Read MoreAcitretin Prescribing Patterns in Women of Childbearing Potential
July 2013 | Volume 12 | Issue 7 | Original Article | 799 | Copyright © July 2013
BACKGROUND: Acitretin is indicated for severe psoriasis, but it is also a potent teratogen whose use should be avoided in women of childbearing potential. Topical medications, phototherapy, cyclospori...
Read MoreResident Rounds. Part III B: Tumor Necrosis Factor-α Antagonists and Alopecia Areata: A Class-Wide Adverse Effect
June 2013 | Volume 12 | Issue 6 | Features | 713 | Copyright © June 2013
Granuloma Annulare Masquerading as Erythema Multiforme
June 2013 | Volume 12 | Issue 6 | Case Reports | 694 | Copyright © June 2013
Erythema multiforme (EM) is a serious cutaneous and/ or mucocutaneous disorder that typically develops within 10-14 days of exposure to an offending medication or infection and resolves within 4 week...
Read MoreInfections Associated With the Use of Tumor Necrosis Factor-α Inhibitors in Psoriasis
March 2013 | Volume 12 | Issue 3 | Original Article | 41 | Copyright © March 2013
Tumor necrosis factor (TNF)-α inhibitors have been shown to increase the risks of overall infection and serious infection in rheumatoid arthritis. However, it is uncertain whether we can draw th...
Read MoreThe Efficacy of Ustekinumab in Psoriasis
March 2013 | Volume 12 | Issue 3 | Original Article | 317 | Copyright © March 2013
Psoriasis is an immune-mediated cutaneous disease affecting 2% of the worldwide population. While topical therapy, phototherapy, oral systemic therapy, and biologic agents have been used, the treatmen...
Read MoreNew-Onset Vitiligo During Long-Term, Stable Infliximab Treatment of Pityriasis Rubra Pilaris
February 2013 | Volume 12 | Issue 2 | Case Reports | 217 | Copyright © February 2013
Incidents of new-onset vitiligo attributed to infliximab therapy for rheumatoid arthritis and ulcerative colitis have been reported. Reported cases share a common theme in that symptoms manifested in ...
Read MoreProgressive Multifocal Leukoencephalopathy and Reversible Progressive Leukoencephalopathy Syndrome in Dermatologic Therapy
February 2013 | Volume 12 | Issue 2 | Original Article | 20 | Copyright © February 2013
Progressive multifocal leukoencephalopathy (PML) is a frequently fatal demyelinating disease of the brain caused by activation of the John Cunningham virus. It typically occurs in immunocompromised pa...
Read MoreEfficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)
February 2013 | Volume 12 | Issue 2 | Original Article | 166 | Copyright © February 2013
Background: Available biologic agents for the treatment of psoriasis in China are limited.
Objectives: The LOTUS study is a phase 3, double-blind, placebo-controlled study that eva...
Read MoreTwo Cases of Hepatitis B in Patients With Moderate to Severe Psoriasis With Ustekinumab
December 2012 | Volume 11 | Issue 12 | Case Reports | 1498 | Copyright © December 2012
Background: Patients with psoriasis who are treated with systemic and biologic therapies may have an increased risk of infections, including hepatitis B virus (HBV). Cytokines that m...
Read MoreClearance of Nasal Staphylococcus aureus Colonization With Triple Antibiotic Ointment
December 2012 | Volume 11 | Issue 12 | Original Article | 1490 | Copyright © December 2012
Background: The prevalence of Staphylococcus aureus colonization of healthcare workers is reported at 30%, with colonization rates for methicillin-resistant S aureusRead More
Treatment of Severe Psoriasis With Ustekinumab During Pregnancy
October 2012 | Volume 11 | Issue 10 | Case Reports | 1240 | Copyright © October 2012
We present the case of a female, aged 22 years, with a long history of recalcitrant pustular psoriasis and psoriatic arthritis, treated with ustekinumab during pregnancy. The result of treatment was a...
Read MorePSOLAR: Design, Utility, and Preliminary Results of a Prospective, International, Disease-Based Registry of Patients With Psoriasis Who are Receiving, or are Candidates for, Conventional Systemic Treatments or Biologic Agents
October 2012 | Volume 11 | Issue 10 | Original Article | 1210 | Copyright © October 2012
Background: Long-term observational studies can better characterize the impact of systemic agents on psoriasis.
Objective: To describe the on-going Psoriasis Longitudinal Assessmen...
Read MoreUstekinumab for Treatment of Plaque Psoriasis in a Patient With Down Syndrome
August 2012 | Volume 11 | Issue 8 | Case Reports | 1000 | Copyright © August 2012
Down syndrome (DS) is the most common chromosomal disorder and a major cause of mental retardation. Down syndrome phenotype is complex and may present a combination of dysmorphic features, congenital ...
Read MoreThe Use of Cyclosporine in Dermatology
August 2012 | Volume 11 | Issue 8 | Original Article | 979 | Copyright © August 2012
Cyclosporine is an immunosuppressive drug that acts selectively on T-cells by inhibiting calcineurin phosphorylase. It has been used in dermatology since its approval for US Food and Drug Administrati...
Read More